Trial record 7 of 3482 for: Recruiting, Not yet recruiting, Available Studies | "Lung Diseases"

Previous Study | Return to List | Next Study

Prospective Data Collection of Patients With Diffuse Parenchymal Lung Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01600378

Recruitment Status : Recruiting

First Posted : May 17, 2012

Last Update Posted : November 8, 2017

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Singapore General Hospital

Study Description

Brief Summary:

The purpose of this study is to generate a prospective database of all patients evaluated for diffuse parenchymal lung diseases to provide much needed data on the various disease aetiologies, incidence and prevalence rates, clinical and radiological presentations, pathologic correlations, disease progression and response to treatment, and final outcomes in this group of patients in Singapore.

Condition or disease
Diffuse Parenchymal Lung Diseases

Study Design


Study Type :	Observational
Estimated Enrollment :	500 participants
Observational Model:	Case-Only
Time Perspective:	Prospective
Official Title:	Prospective Data Collection of Clinical, Pulmonary Function, Radiological, Bronchoscopic and Fibered Confocal Fluorescence Microscopy Imaging, and Pathological Characteristics in Patients With Diffuse Parenchymal Lung Diseases
Study Start Date :	May 2012
Estimated Primary Completion Date :	April 2022
Estimated Study Completion Date :	April 2022

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Pulmonary alveolar microlithiasis

MedlinePlus related topics: Interstitial Lung Diseases Lung Diseases

Genetic and Rare Diseases Information Center resources: Idiopathic Pulmonary Fibrosis

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

Final diagnoses of patients presenting with diffuse parenchymal lung disease after complete evaluation [ Time Frame: 3 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	21 Years to 90 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients evaluated for diffuse parenchymal lung diseases

Criteria

Inclusion Criteria:

All patients 21 years old and older diagnosed with suspected diffuse parenchymal lung disease (multi-lobar pulmonary infiltrates)

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01600378

Contacts


Contact: Su Ying Low, BMBCh	+65 63214700	low.su.ying@sgh.com.sg

Locations


Singapore
Singapore General Hospital	Recruiting
Singapore, Singapore, 169608
Contact: Su Ying Low, BMBCh +65 3214700 low.su.ying@sgh.com.sg
Principal Investigator: Su Ying Low, BMBCh

Sponsors and Collaborators

Singapore General Hospital

Investigators


Principal Investigator:	Su Ying Low, BMBCh	Singapore General Hospital

More Information

Publications:

American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304. Review. Erratum in: Am J Respir Crit Care Med2002 Aug 1;166(3):426.

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.


Responsible Party:	Singapore General Hospital
ClinicalTrials.gov Identifier:	NCT01600378 History of Changes
Other Study ID Numbers:	2012/245/Cilddatabase
First Posted:	May 17, 2012 Key Record Dates
Last Update Posted:	November 8, 2017
Last Verified:	November 2017

Keywords provided by Singapore General Hospital:


diffuse parenchymal lung disease interstitial lung disease idiopathic pulmonary fibrosis

Additional relevant MeSH terms:


Lung Diseases Lung Diseases, Interstitial Respiratory Tract Diseases

To Top